December 2024 Submission of NCCR Data in SEER*Stat			
	Item # refers	to the NAACCR item number - see https://apps.naaccr.org/data-dictionary/data-dict	ionary/version=24/chapter-view/
	CS= Collabor	ative Staging	
	* indicates th	nat a field is only available in the database without AZ and FL	
Name	NAACCR	Description	
	Item #		Category name
Age recode with single ages and 85+		Patient's age at diagnosis with all ages over 85 grouped together. In rate sessions	
		this is the population age variable.	Age at Diagnosis
Sex	220	Includes 1= Male and 2=Female from Sex [NAACCR Item #220] plus a total of male	
		and female. This is used to link to the correct populations for males and females	
		when calculating sex-specific rates.	Race, Sex, Year Dx
ear of Diagnosis	390	From NAACCR Name=Date of Diagnosis, Item #=390	Race, Sex, Year Dx
PRCDA 2020		This data item identifies whether or not the county of diagnosis is served by PRCDA.	
		The primary use of this field is to be able to limit analyses of AI/AN race to areas	
		served by PRCDA.	
		See https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity OR	
		https://seer.cancer.gov/seerstat/variables/countyattribs/	Race, Sex, Year Dx
Race Recode (W, B, AIAN, API)		Caution should be exercised when using this variable. For more information, see	
		https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/.	
			Race, Sex, Year Dx
Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)		Caution should be exercised when using this variable. For more information, see	
		https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/.	
			Race, Sex, Year Dx
CCC site recode 3rd edition/IARC 2017		A site/histology recode that is mainly used to analyze data on children. The recode	
		was applied to all cases no matter the age in order that age comparisons can be	
		made with these groupings. Based on ICD-O-3. Note that cases diagnosed before	
		2001 were not coded under ICD-O-3 and were converted to ICD-O-3 and may not	
		have the specificity of cases after 2000 that were coded directly under ICD-O-3. For	
		more information on this International Classification of Childhood Cancer (ICCC) site	
		recode, see https://seer.cancer.gov/iccc	
			Site and Morphology
ICCC site recode extended 3rd edition/IARC 2017		Based on ICD-O-3. For more information on this International Classification of	
		Childhood Cancer (ICCC) site/histology recode, see https://seer.cancer.gov/iccc.	
		While the recode is normally used for childhood cancers, it is on the file for all ages	
		so that childhood cancers could be compared across age groups. For more	
		information, see https://seer.cancer.gov/iccc/iccc-iarc-2017.html	
		minormation, see https://seer.canter.gov/icce/icce-iare-2017.iitiiii	Site and Morphology
AYA site recode 2020 Revision		A site/histology recode that is mainly used to analyze data on adolescent and young	,
		adults. The recode was applied to all cases no matter the age in order that age	
		comparisons can be made with these groupings. For more information, see	
		https://seer.cancer.gov/ayarecode/	
		incho.// seer.cancer.gov/ayarecode/	Site and Morphology

Name	NAACCR	Description	
	Item #		Category name
Primary site - labeled	400	This provides the primary site code in ICD-O-3 and a descriptive primary site label.	
		Note that the label is the preferred ICD-O-3 bolded name and there may be other	
		sites or sub-sites included in the code but not reflected in the preferred term. Refer	
		to ICD-O-3 for further information.	Site and Morphology
Primary Site		Codes are found in the Topography section of the International Classification of	
		Diseases for Oncology (ICD-O) 3rd edition.	Site and Morphology
Histologic type ICD-O-3	522	Based on histology codes in ICD-O-3. Cases diagnosed before 2001 were coded in	one and morphology
		earlier versions and converted to ICD-O-3 and coded directly for 2001+.	
			Site and Morphology
Behavior code ICD-O-3		Based on behavior codes in ICD-O-3. Behavior code has had the same definitions in	Site and Morphology
Berlavior code icb-o-3		previous versions but may be associated differently with histologies over time. For	
		example, borderline of the ovary were considered malignant in ICD-O-2 but benign	
		in ICD-O-3. Cases diagnosed before 2001 were coded in earlier versions and	
		converted to ICD-O-3 and coded directly for 2001+. In situ bladder cases have been	
		converted to malignant in this field. See Behavior recode for consistency over time.	
			Cita and Manual alama
Lymphoid neoplasm recode 2021 Revision		A site/histology recode that is mainly used to analyze data on lymphoma sub-types.	Site and Morphology
Lymphold neoplasm recode 2021 Revision		Based on ICD-O-3. Note that cases diagnosed before 2001 were not coded under	
		ICD-O-3 and were converted to ICD-O-3 and may not have the specificity of cases	
		after 2000 that were coded directly under ICD-O-3. For more information, see	
		https://seer.cancer.gov/lymphomarecode/	Site and Morphology
Grade (thru 2017)	440	From NAACCR Name=Grade, Item #=440	Site and Worphology
		, , , , , , , , , , , , , , , , , , , ,	Site and Morphology
Grade Clinical (2018+)	3843	Refer to the most recent version of the NAACCR SSDI Manual for additional site-	1 0,
		specific instructions.	Cite and Marchalagy
Grade Pathological (2018+)	2011	Refer to the most recent version of the NAACCR SSDI Manual for additional site-	Site and Morphology
Grade Patriological (2010+)	3044	specific instructions.	Site and Morphology
Diagnostic confirmation	490	From NAACCR Name=Diagnostic Confirmation, Item #=490	Site and Morphology
ICD-O-3 Hist/behavior, labeled		Labeled version of ICD-O-3 Histology/Behavior values for all behaviors. See	Site and Morphology
132 3 1.134 Schartor, labeled		SEED*Stat dictionary for labels	
		·	Site and Morphology
ICD-O-3 Hist/behavior, malig, labeled		Labeled version of ICD-O-3 Histology Behavior values for malignant tumors. All non-	
		malignant tumors are grouped into one value. See SEER*Stat dictionary for labels.	Cite and Manufacture
Sebama ID (2019)	2000		Site and Morphology
Schema ID (2018+)	3800	This variable allows the linkage of 2018+ Site-Specific Data Items (SSDIs), including grade data items, with the appropriate site/histology grouping.	
Latera 19			Site and Morphology
Laterality	410	From NAACCR Name=Laterality, Item #=410	Site and Morphology

Name	NAACCR	Description	
	Item #		Category name
Behavior recode for analysis		This recode was created so that data analyses could eliminate major groups of	
·		histologies/behaviors that weren't collected consistently over time, for example	
		benign brain, myelodysplastic syndromes, and borderline tumors of the ovary.	
		Created from ICD-O-3 behavior and histology. For more information, see	
		https://seer.cancer.gov/behavrecode	Site and March Labor
Site records ICD O 2 /MILIO 2009		A record hazard an Drimany Cita and Histology in and a to make analysis of	Site and Morphology
Site recode ICD-O-3/WHO 2008		A recode based on Primary Site and Histology in order to make analyses of	
		site/histology groups easier. For example, the lymphomas are excluded from	
		stomach and Kaposi and mesothelioma are separate categories based on histology.	
		For more information, see https://seer.cancer.gov/siterecode/icdo3_dwhoheme/	
			Site and Morphology
Summary Stage (2004+)		Combined Summary Stage field to facilitate stage analyses over time. Created from	
		Summary Stage 2000 (2004-2017) & Derived Summary Stage 2018 (2018+). Due to	
		inconsistency of details for regional stage between the 2 fields, all regional codes	
		collapsed into into one category.	Stage - LRD (Summary and Historic)
SEER summary stage 2000 (2001-2003)		SEER Summary Stage 2000 for years 2001-2003.	Stage - LRD (Summary and Historic)
RX summsurg prim site (2003+)	1290	NAACCR Name=RX SummSurg Prim Site, Item #=1290. The information in this field	
		is site-specific. The amount/detail of information has varied over time and caution	
		should be used when looking at trends over time. For site-specific codes, see	
		Appendix C of https://seer.cancer.gov/tools/codingmanuals/	
			Therapy
RX summsurg oth reg/dis (2003+)	1294	From NAACCR Name=RX SummSurg Oth Reg/Dis, Item #=1294	Therapy
RX summsurg/rad seq (2010+)		From NAACCR Name=RX SummSurg/Rad Seq, Item #=1380	Therapy
Reason for no CA dir surg (2006+)	1340	From NAACCR Name=Reason for No Surgery, Item #=1340	Therapy
RX SummSystemic Surg Seq (2010+)	1639	From NAACCR Name=RX SummSystemic/Sur Seq, Item #=1639	Therapy
RX SummScope Reg LN Sur (2003+)	1292	NAACCR Name=RX SummScope Reg LN Sur, Item #=1292. Changed to Unknown	
		or not applicable for breast cancer cases.	Therapy
Radiation recode (2003+)		Created from radiation and Phase 1 (and 2/3 when available) modalities and reason	
		no radiation.	
			Therapy
Chemotherapy recode (yes, no/unk) (2010+)		Created from RX SummChemo, Item #=1390	Therapy
CS tumor size (2004-2015)	2800	From NAACCR Name=CS Tumor Size, Item #=2800	Extent of Disease
CS extension (2004-2015)	2810	From NAACCR Name=CS Extension, Item #=2810	Extent of Disease
CS lymph nodes (2004-2015)	2830	From NAACCR Name=CS Lymph Nodes, Item #=2830	Extent of Disease
CS mets at dx (2004-2015)	2850	From NAACCR Name=CS Mets at DXs, Item #=2850	Extent of Disease
Regional nodes examined (1998+)	830	From NAACCR Name=Regional Nodes Examined, Item #=830	Extent of Disease
Regional nodes positive (1998+)	820	From NAACCR Name=Regional Nodes Positive, Item #=820	Extent of Disease
Tumor Size Summary (2016+)	756	From NAACCR Name=Tumor Size Summary, Item #=756	Extent of Disease
Turnor Size Sullilliary (2010+)	/30	TOTH WARCON WATER-TUTTOL SIZE SUITHINGLY, ILEH #-730	Extent of Disease

Name	NAACCR	Description	
	Item #		Category name
Lymph-vascular Invasion (2018+ varying by schema)	1182	Available only for testis and penis because it is needed for AJCC 6th & 7th ed	
		staging.	Extent of Disease
Derived HER2 Recode (2010+)		Created with combined information from several CS site-specific factors (2010-	
		2017) and HER2 Overall Summary (2018+) (NAACCR Item #=3855). For more	
		information, see https://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html.	
		Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND EOD Schema Id.	
			Extent of Disease
ER Status Recode Breast Cancer (2010+)		Created with combined information from CS site-specific factor 1 (2010-2017)	
		(NAACCR Item #=2880) and Estrogen Receptor Summary (2018+) (NAACCR Item	
		#=3827). Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND EOD	
		Schema Id AND Site recode ICD-O-3/WHO 2008.	Extent of Disease
PR Status Recode Breast Cancer (2010+)		Created with combined information from CS site-specific factor 2 (2010-2017)	
` ,		(NAACCR Item #=2890) and Progesterone Receptor Summary (2018+) (NAACCR	
		Item #=3915). Coded for cases coded as Breast in TNM 7/CS v0204+ Schema AND	
		EOD Schema Id AND Site recode ICD-O-3/WHO 2008.	Extent of Disease
	1784	NAACCR Item #=1784, created using complete dates, including days, therefore may	
		differ from survival time calculated from year and month only. Blended means that	
		the Active Followup fields are used for some registries and Presumed Alive	
		Followup fields are used for others. For more information, see	
Survival months - blended *		https://seer.cancer.gov/survivaltime.	Cause of Death (COD) and Follow-up
		NAACCR Item #=1783, created using complete dates, including days, therefore may	
		differ from survival time calculated from year and month only. Blended means that	
		the Active Followup fields are used for some registries and Presumed Alive	
		Followup fields are used for others. For more information, see	
Survival months flag - blended *		https://seer.cancer.gov/survivaltime.	Cause of Death (COD) and Follow-up
		Any patient that dies after the follow-up cut-off date is recoded to alive as of the	
Vital status recode *		cut-off date.	Cause of Death (COD) and Follow-up
Record number recode	1775	Sequentially numbers a person's tumors within each submission. Order is based on	
		date of diagnosis and then sequence #.	Multiple Primary Fields
Sequence numbercentral	380	NAACCR Name=Sequence NumberCentral, Item #=380	Multiple Primary Fields
Fibrosis Score (2018+)	3835	NAACCR Name=Fibrosis Score, Item #=3835.	Site-Specific Data Items
Brain Molecular Markers (2018+)	3816	NAACCR Name=Brain Molecular Markers, Item #=3816.	Site-Specific Data Items
Breslow Tumor Thickness (2018+)	3817	NAACCR Name=Breslow Tumor Thickness, Item #=3817.	Site-Specific Data Items
PSA Lab Value Recode (2010+)		Coded for cases coded as Prostate in BOTH TNM 7/CS v0204+ Schema Recode &	
		EOD Schema Id Recode. Created from NAACCR Item #3920 & CS site-specific factor	
		1 (NAACCR #2880). Measurement in nanograms/milliliter (ng/ml). For more	
		information, see https://seer.cancer.gov/seerstat/variables/seer/ssdi/	
			Site-Specific Data Items
LDH Pretreatment Lab Value (2018+)	3932	NAACCR Name=LDH Lab Value, Item #=3932.	Site-Specific Data Items

Name	NAACCR	Description	
	Item #		Category name
Age recode <1 year olds		The age recode variable is based on Age at Diagnosis (single-year ages). This recode	
		has 19 age groups in the age recode variable (< 1 year, 1-4 years, 5-9 years,, 85+	
		years).	Race and Age (case data only)
	1788	NAACCR Item #=1788, month of diagnosis from survival months field creation	
Month of diagnosis recode *			Dates
	1782	The earlier of the Year of Last Contact (NAACCR #1750) and the study cutoff.	
		Blended means that the Active Followup fields are used for some registries and	
		Presumed Alive Followup fields are used for others. Coded survival for some	
Year of last contact recode blended *		registries and presumed alive for others.	Dates
CoC Accredited Flag (2018+)	2152	CoC Accredited Flag is assigned at the point and time of data abstraction to label an	
		abstract being prepared for an analytic cancer case at a facility accredited by the	
		Commission on Cancer (CoC). The flag may be assigned manually or can be	
		defaulted by the registry's software.	Other
Type of Reporting Source	500	Contains information on where the information from this case came. Is used in	
		survival analysis to eliminate cases which are found at autopsy or the only	
		information is from a death certificate.	Other
Yost Quintile (US)	9610	For more information, refer to the "SES Quintiles" section of	
		https://seer.cancer.gov/seerstat/databases/census-tract/index.html	Tract Derived